Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | Director | May 20, 2026 | May 22, 2026 |
| Elevance Health, Inc.ELV · Entity 2934 | Director | May 13, 2026 | May 15, 2026 |
| FRACTYL HEALTH, INC.GUTS · Entity 6700 | Director | June 11, 2025 | June 13, 2025 |
| Hudson Executive Investment Corp. IIHCII · Entity 130674 | Director | April 13, 2021 | April 14, 2021 |
| Korsana Biosciences, Inc.CYCN · Entity 7698 | Director | June 16, 2020 | June 18, 2020 |
| SQZ Biotechnologies CoSQZ · Entity 112267 | Director · 10% owner | June 14, 2023 | June 15, 2023 |
| Talkspace, Inc.HEC · Entity 22747 | Director | June 08, 2020 | June 08, 2020 |
| X4 Pharmaceuticals, IncASNS · Entity 5638 | Director | June 05, 2018 | June 07, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date May 20, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,049 |
Reported balance
After 2026-05-20 transaction · row 1
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 838 · Balance 24,049 F1: These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $298.48 · Expires 2036-05-20 | Direct | 1,802 |
Reported balance
After 2026-05-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-20 · Grant · Acquired 1,802 · Balance 1,802 F2: The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.
F2: The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.
Elevance Health, Inc.
Report date May 13, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 781 |
Reported balance
After 2026-05-13 transaction · row 1
1 source rowRow 1 · 2026-05-13 · Grant · Acquired 563 · Balance 781 F1: Deferred stock units accrued under the Elevance Health, Inc. ("Company") Board of Directors Compensation Program. F2: The deferred stock units shall be payable in Company common stock upon the first to occur of (a) five years from the date of grant or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Deferred stock units accrued under the Elevance Health, Inc. ("Company") Board of Directors Compensation Program.
F2: The deferred stock units shall be payable in Company common stock upon the first to occur of (a) five years from the date of grant or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan.
FRACTYL HEALTH, INC.
Report date June 11, 2025 · Filed June 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.27 · Expires 2035-06-10 | Direct | 22,500 |
Reported balance
After 2025-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-11 · Grant · Acquired 22,500 · Balance 22,500 F1: The stock option was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's non-employee director compensation policy. The stock option will vest and become exercisable in a single installment on the earlier of (i) the date of the next annual meeting of stockholders or (ii) the first anniversary of the grant in each case subject to continued service on the Issuer's board of directors as a non-employee director through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's non-employee director compensation policy. The stock option will vest and become exercisable in a single installment on the earlier of (i) the date of the next annual meeting of stockholders or (ii) the first anniversary of the grant in each case subject to continued service on the Issuer's board of directors as a non-employee director through the vesting date.
Hudson Executive Investment Corp. II
Report date April 13, 2021 · Filed April 14, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table II · derivative / convertible security | Direct | 20,000 |
Reported balance
After 2021-04-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-04-13 · Purchase · Acquired 20,000 · Balance 20,000 F1: The shares of Class B common stock are convertible for shares of the Issuer's Class A common stock as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-251848) (the "Registration Statement") and have no expiration date |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Class B common stock are convertible for shares of the Issuer's Class A common stock as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-251848) (the "Registration Statement") and have no expiration date
Korsana Biosciences, Inc.
Report date June 16, 2020 · Filed June 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.46 · Expires 2030-06-16 | Direct | 10,000 |
Reported balance
After 2020-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-16 · Grant · Acquired 10,000 · Balance 10,000 F1: The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date.
SQZ Biotechnologies Co
Report date June 14, 2023 · Filed June 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.54 · Expires 2033-06-13 | Direct | 39,875 |
Reported balance
After 2023-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-14 · Grant · Acquired 39,875 · Balance 39,875 F1: The option vests and become exercisable on the earlier of (i) June 14, 2024 or (ii) the day immediately prior to the date of the next annual meeting of stockholders following the date of grant, in each case subject to the recipient's continued service on the Board at such time. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and become exercisable on the earlier of (i) June 14, 2024 or (ii) the day immediately prior to the date of the next annual meeting of stockholders following the date of grant, in each case subject to the recipient's continued service on the Board at such time.
Talkspace, Inc.
Report date June 08, 2020 · Filed June 08, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-06-08 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The shares of Class B common stock are convertible for shares of the Issuer's Class A common stock as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-238583) (the "Registration Statement") and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Class B common stock are convertible for shares of the Issuer's Class A common stock as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-238583) (the "Registration Statement") and have no expiration date.
X4 Pharmaceuticals, Inc
Report date June 05, 2018 · Filed June 07, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.99 · Expires 2028-06-04 | Direct | 10,000 |
Reported balance
After 2018-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-05 · Grant · Acquired 10,000 · Balance 10,000 F1: The option becomes exercisable as to 1/12th of the shares underlying the award on the one-month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option becomes exercisable as to 1/12th of the shares underlying the award on the one-month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director through each applicable vesting date.
Past disclosures · reporting ended (4)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Blue Buffalo Pet Products, Inc.
Report date April 24, 2018 · Filed April 24, 2018
Section 16 reporting ended · disclosed 2018-04-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-04-24 transaction · row 1
1 source rowRow 1 · 2018-04-24 · Disposition to issuer · Disposed 14,819 · Balance 0 F1: On April 24, 2018, General Mills, Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Bravo Merger Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of February 22, 2018 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F2: At the effective time of the Merger, each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $40.00 in cash, without interest and after giving effect to any required withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 24, 2018, General Mills, Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Bravo Merger Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of February 22, 2018 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger").
F2: At the effective time of the Merger, each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $40.00 in cash, without interest and after giving effect to any required withholding taxes.
Camp4 Therapeutics Corp
Report date September 11, 2025 · Filed September 11, 2025
Jointly reported with Polaris Management Co. VII, L.L.C., Polaris Partners VII, L.P., Polaris Entrepreneurs' Fund VII, L.P., Polaris Partners X, L.P., Polaris Partners GP X, L.L.C., Chee Brian
Section 16 reporting ended · disclosed 2025-09-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,825,500 |
Reported balance
After 2025-09-11 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2025-09-11 · Purchase · Acquired 1,221,721 · Balance 2,825,500 F1: On September 11, 2025, each of Polaris Partners VII, L.P. ("PP VII") and Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII") acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and the investors party thereto at a purchase price of $1.53 per share. F2: The reported securities are owned directly by PP VII. Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 197,661 |
Reported balance
After 2025-09-11 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2025-09-11 · Purchase · Acquired 85,468 · Balance 197,661 F1: On September 11, 2025, each of Polaris Partners VII, L.P. ("PP VII") and Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII") acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and the investors party thereto at a purchase price of $1.53 per share. F3: The reported securities are owned directly by PEF VII. PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 909,090 |
Reported balance
Holding disclosure · report date 2025-09-11 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 909,090 F4: The reported securities are owned directly by Polaris Partners X, L.P. ("PP X"). Polaris Partners GP X, L.L.C. ("PPGP X") is the general partner of PP X. Each of Amy Schulman and Brian Chee are the managing members of PPGP X (the "PPGP X Managing Members"). Amir Nashat ("Mr. Nashat"), a member of the Issuer's board of directors, is an interest holder of PPGP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat, in their respective capacities with respect to PPGP X, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PPGP X Managing Members, Mr. Nashat or PPGP X is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 11, 2025, each of Polaris Partners VII, L.P. ("PP VII") and Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII") acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and the investors party thereto at a purchase price of $1.53 per share.
F2: The reported securities are owned directly by PP VII. Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
F3: The reported securities are owned directly by PEF VII. PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
F4: The reported securities are owned directly by Polaris Partners X, L.P. ("PP X"). Polaris Partners GP X, L.L.C. ("PPGP X") is the general partner of PP X. Each of Amy Schulman and Brian Chee are the managing members of PPGP X (the "PPGP X Managing Members"). Amir Nashat ("Mr. Nashat"), a member of the Issuer's board of directors, is an interest holder of PPGP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat, in their respective capacities with respect to PPGP X, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PPGP X Managing Members, Mr. Nashat or PPGP X is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
IRONWOOD PHARMACEUTICALS INC
Report date April 01, 2019 · Filed April 03, 2019
Section 16 reporting ended · disclosed 2019-04-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 38,242 |
Reported balance
After 2019-04-01 transaction · row 1
1 source rowRow 1 · 2019-04-01 · Disposition to issuer · Disposed 4,056 · Balance 38,242 F1: Represents the disposition of 4,056 shares of restricted stock in connection with the separation of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. in exchange for restricted shares of Cyclerion Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the disposition of 4,056 shares of restricted stock in connection with the separation of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. in exchange for restricted shares of Cyclerion Common Stock.
PFIZER INC
Report date December 31, 2013 · Filed January 03, 2014
Section 16 reporting ended · disclosed 2014-01-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock Units SSPSEC Table II · derivative / convertible security | Direct | 5,075 |
Reported balance
After 2013-12-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2013-12-31 · Grant · Acquired 59 · Balance 5,075 F1: Each unit represents one phantom share of common stock. F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. |
Filing footnotes · ownership attribution and instrument terms
F1: Each unit represents one phantom share of common stock.
F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 24, 2012 Filed Feb 27, 2012 23:12 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 37,626 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-005639 · doc4.xml · nonDerivative · entry 2 SCHULMAN AMY W · CIK 0001438226 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,348 F2 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 23:12 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 144,033 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-12-005639 · doc4.xml · derivative · entry 7 SCHULMAN AMY W · CIK 0001438226 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,033 Underlying: Common Stock · 144,033 shares Expires 2019-02-23 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 23:12 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 169,903 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-12-005639 · doc4.xml · derivative · entry 6 SCHULMAN AMY W · CIK 0001438226 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,903 Underlying: Common Stock · 169,903 shares Expires 2017-02-23 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 23:12 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 32,988 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-005639 · doc4.xml · nonDerivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,722 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| June 30, 2011 Filed Jul 5, 2011 14:47 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 57,864 | $20.60 | $1,191,998.40 |
DisclosureSEC source: 0001225208-11-017230 · doc4.xml · nonDerivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,636 F1 · shares: Represents withholding of shares to satisfy tax obligations upon vesting of restricted stock units. Read SEC document |
| March 15, 2011 Filed Mar 16, 2011 20:12 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 1,491 | $19.76 | $29,462.16 |
DisclosureSEC source: 0001225208-11-009812 · doc4.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,473 Underlying: Common Stock · 1,491 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| February 24, 2011 Filed Mar 1, 2011 02:24 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 145,068 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001223203-11-000005 · primary_doc.xml · derivative · entry 5 SCHULMAN AMY W · CIK 0001438226 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,068 Underlying: Common Stock · 145,068 shares Expires 2018-02-24 F3 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F3 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 24, 2011 Filed Mar 1, 2011 02:24 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 175,234 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001223203-11-000005 · primary_doc.xml · derivative · entry 4 SCHULMAN AMY W · CIK 0001438226 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,234 Underlying: Common Stock · 175,234 shares Expires 2016-02-24 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 24, 2011 Filed Mar 1, 2011 02:24 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 51,615 | $0.00 | $0.00 |
DisclosureSEC source: 0001223203-11-000005 · primary_doc.xml · nonDerivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,194 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 24, 2011 Filed Mar 1, 2011 15:54 UTC Amendment | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 145,068 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001223203-11-000006 · primary_doc.xml · derivative · entry 2 SCHULMAN AMY W · CIK 0001438226 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,068 Underlying: Common Stock · 145,068 shares Expires 2018-02-24 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 24, 2011 Filed Mar 1, 2011 15:54 UTC Amendment | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 175,234 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001223203-11-000006 · primary_doc.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,234 Underlying: Common Stock · 175,234 shares Expires 2016-02-24 F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| December 31, 2010 Filed Jan 3, 2011 22:31 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 90 | $17.51 | $1,575.90 |
DisclosureSEC source: 0001225208-11-000284 · doc4.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,963 Underlying: Common Stock · 90 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| December 15, 2010 Filed Dec 17, 2010 22:30 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 93 | $17.08 | $1,588.44 |
DisclosureSEC source: 0001225208-10-027434 · doc4.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,873 Underlying: Common Stock · 93 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 30, 2010 Filed Dec 2, 2010 00:28 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 96 | $16.30 | $1,564.80 |
DisclosureSEC source: 0001225208-10-026047 · doc4.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,780 Underlying: Common Stock · 96 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 15, 2010 Filed Nov 16, 2010 23:52 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 114 | $16.75 | $1,909.50 |
DisclosureSEC source: 0001225208-10-025028 · doc4.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,684 Underlying: Common Stock · 114 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 29, 2010 Filed Nov 1, 2010 20:26 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 90 | $17.42 | $1,567.80 |
DisclosureSEC source: 0001225208-10-023841 · doc4.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,570 Underlying: Common Stock · 90 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 15, 2010 Filed Oct 18, 2010 23:06 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 89 | $17.75 | $1,579.75 |
DisclosureSEC source: 0001225208-10-023194 · doc4.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,480 Underlying: Common Stock · 89 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 30, 2010 Filed Oct 1, 2010 19:31 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 92 | $17.17 | $1,579.64 |
DisclosureSEC source: 0001225208-10-021682 · doc4.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,391 Underlying: Common Stock · 92 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 15, 2010 Filed Sep 17, 2010 12:17 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 89 | $17.27 | $1,537.03 |
DisclosureSEC source: 0001225208-10-020979 · doc4.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,299 Underlying: Common Stock · 89 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 31, 2010 Filed Sep 2, 2010 12:08 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 101 | $15.91 | $1,606.91 |
DisclosureSEC source: 0001225208-10-020186 · doc4.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,210 Underlying: Common Stock · 101 shares Expires not disclosed F2 · derivative.exercise_price: Each unit represents one phantom share of common stock. F1 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F1 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 13, 2010 Filed Aug 17, 2010 15:20 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 110 | $16.08 | $1,768.80 |
DisclosureSEC source: 0001225208-10-019327 · doc4.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,109 Underlying: Common Stock · 110 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 30, 2010 Filed Aug 3, 2010 15:19 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 106 | $15.00 | $1,590.00 |
DisclosureSEC source: 0001225208-10-018094 · doc4.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 999 Underlying: Common Stock · 106 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 15, 2010 Filed Jul 16, 2010 20:54 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 106 | $14.87 | $1,576.22 |
DisclosureSEC source: 0001225208-10-017307 · doc4.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 893 Underlying: Common Stock · 106 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 30, 2010 Filed Jul 1, 2010 20:53 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 111 | $14.26 | $1,582.86 |
DisclosureSEC source: 0001225208-10-016177 · doc4.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 787 Underlying: Common Stock · 111 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 15, 2010 Filed Jun 16, 2010 19:05 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 102 | $15.52 | $1,583.04 |
DisclosureSEC source: 0001225208-10-015312 · doc4.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 676 Underlying: Common Stock · 102 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 28, 2010 Filed Jun 1, 2010 21:55 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 105 | $15.23 | $1,599.15 |
DisclosureSEC source: 0001225208-10-014354 · doc4.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 574 Underlying: Common Stock · 105 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 14, 2010 Filed May 18, 2010 19:56 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 102 | $16.20 | $1,652.40 |
DisclosureSEC source: 0001225208-10-013296 · doc4.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 469 Underlying: Common Stock · 102 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 30, 2010 Filed May 3, 2010 19:43 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 94 | $16.72 | $1,571.68 |
DisclosureSEC source: 0001225208-10-011623 · doc4.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367 Underlying: Common Stock · 94 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 15, 2010 Filed Apr 16, 2010 21:38 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 94 | $16.99 | $1,597.06 |
DisclosureSEC source: 0001225208-10-010502 · doc4.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273 Underlying: Common Stock · 94 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 31, 2010 Filed Apr 1, 2010 22:44 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 90 | $17.15 | $1,543.50 |
DisclosureSEC source: 0001225208-10-009472 · doc4.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179 Underlying: Common Stock · 90 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 15, 2010 Filed Mar 17, 2010 13:23 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 89 | $17.26 | $1,536.14 |
DisclosureSEC source: 0001225208-10-008376 · doc4.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89 Underlying: Common Stock · 89 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| February 25, 2010 Filed Mar 2, 2010 02:02 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 84,459 | $0.00 Strike: $17.69 | $0.00 |
DisclosureSEC source: 0001225208-10-006403 · doc4.xml · derivative · entry 4 SCHULMAN AMY W · CIK 0001438226 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,459 Underlying: Common Stock · 84,459 shares Expires 2015-02-25 F3 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F3 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 25, 2010 Filed Mar 2, 2010 02:02 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 36,211 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-10-006403 · doc4.xml · nonDerivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,653 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 26, 2009 Filed Mar 2, 2009 23:26 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 111,940 | $0.00 Strike: $12.70 | $0.00 |
DisclosureSEC source: 0000078003-09-000038 · sch1975.xml · derivative · entry 4 SCHULMAN AMY W · CIK 0001438226 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,940 Underlying: Common Stock · 111,940 shares Expires 2014-02-26 F3 · derivative.exercise_date: The stock appreciation rights will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant F3 · derivative.expiration_date: The stock appreciation rights will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant Read SEC document |
| February 26, 2009 Filed Mar 2, 2009 23:26 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 33,911 | $0.00 | $0.00 |
DisclosureSEC source: 0000078003-09-000038 · sch1975.xml · nonDerivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,685 F1 · shares: The reported transaction constitutes the grant of restricted stock units. Read SEC document |
| June 30, 2008 Filed Jul 1, 2008 18:59 UTC | PFIZER INC PFE · Entity 2863 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $17.47 | $0.00 |
DisclosureSEC source: 0000078003-08-000160 · sch1792.xml · derivative · entry 3 SCHULMAN AMY W · CIK 0001438226 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2018-06-29 Read SEC document |
| June 30, 2008 Filed Jul 1, 2008 18:59 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000078003-08-000160 · sch1792.xml · nonDerivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,000 F1 · shares: The reported transaction constitutes the grant of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.